**Chinese Library Classification No.** R445; R741

Introduction {#sec1-1}
============

Vascular cognitive impairment represents the entire spectrum of cognitive impairments associated with vascular pathology, ranging from mild cognitive impairment to fully developed dementia (Gorelick et al., 2011; Zhao et al., 2012a). Deficits in executive function/attention are regarded as hallmarks of vascular cognitive impairment and have been related to chronic deficiencies in frontal blood flow (O'Brien et al., 2003; Hachinski et al., 2006). In our previous studies, we characterized the neuropsychological, hemodynamic, and structural changes of early stage vascular cognitive impairment (Cao et al., 2010; Lei et al., 2016). However, the details regarding microstructural damage in vascular cognitive impairment remain unclear.

Moyamoya disease and cerebrovascular atherosclerotic disease are both chronic progressive cerebrovascular steno-occlusive diseases that are commonly reported in the field of vascular cognitive impairment with prolonged cerebral hypoperfusion (Weinberg et al., 2011; Marshall et al., 2014). In cases of both adult moyamoya disease and adult cerebrovascular atherosclerotic disease, vascular cognitive impairment has been documented as the consequence of ischemic damage that resulted from dynamic factors such as cerebral hypoperfusion rather than to abnormal brain structure (Bos et al., 2012; Karzmark et al., 2012). Thus, studies of moyamoya disease and cerebrovascular atherosclerotic disease offer us a good chance to understand the characteristics of vascular cognitive impairment.

Although the two diseases share similar clinical vascular cognitive impairment features, the etiology and pathogenesis of their vascular cognitive impairments are apparently different. Vascular cognitive impairment in moyamoya disease is associated with an inflammatory process of the central nervous system and is characterized by the development of collateral vessels that compensate for the significant narrowing of the basal vasculature (Soriano et al., 2002; Kazumata et al., 2015). In contrast, vascular cognitive impairment in cerebrovascular atherosclerotic disease is associated with both calcified atherosclerotic plaque lesions and arterial intima-media thickness, irrespective of demographic characteristics or major vascular risk factors (van Oijen et al., 2007; Bos et al., 2012; Wendell et al., 2012; Reis et al., 2013). Additionally, compared with cerebrovascular atherosclerotic disease, cerebral blood flow in moyamoya disease is reported to be both relatively centrally preserved and consistently high in all supratentorial regions (Obara et al., 1997; Schubert et al., 2014).

Focal atrophy of the cerebral cortex is reported to be caused by chronic regional hemodynamic disturbances and contribute to the development of vascular cognitive impairment (Wendell et al., 2012; Lei et al., 2016). Additionally, cerebral white matter is highly vulnerable to ischemia (Pantoni et al., 1996; Vermeer et al., 2003), and the Wallerian degeneration of axons projecting from cortical regions related to cognitive performance is another proposed mechanism underlying vascular cognitive impairment (Balucani and Silvestrini, 2011; Calviere et al., 2012). To the best of our knowledge, few reports have evaluated these two major diseases that include vascular cognitive impairment, particularly in terms of their respective microstructural damage. Based on a recent study that compared perfusion patterns in moyamoya disease and cerebrovascular atherosclerotic disease (Schubert et al., 2014), we hypothesize that the spatial patterns of microstructural damage in these two diseases are similar to their perfusion patterns. The aim of the present study was to investigate the pattern of microstructural damage in vascular cognitive impairment by comparing the two diseases, thus helping us better understand the pathophysiology of vascular cognitive impairment.

Participants and Methods {#sec1-2}
========================

Participants {#sec2-1}
------------

Thirty-four adult patients with moyamoya disease and twenty-seven patients with cerebrovascular atherosclerotic disease were consecutively enrolled at the department of neurosurgery between May and August 2013 and matched for demographic characteristics. Patients were diagnosed based on digital subtraction angiography and in accordance with published guidelines (Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis and Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases, 2012). All participants were Chinese nationals aged 18--60 years, right-handed, with no evidence of infarct in the cerebral cortex, basal ganglia, brainstem, cerebellum, or any intracerebral hemorrhage. Participants with cysts in their cerebral subcortical white or with small spots of hyperintense signals smaller than an arbitrary cutoff of 8 mm on T2 images were included (Hachinski et al., 2006; Lei et al., 2016). Patients with extracranial internal carotid artery stenosis or occlusion were excluded from the cerebrovascular atherosclerotic disease group, and patients with only unilateral vascular damage were ruled out from both groups to keep them more comparable. Through advertisements, we also recruited 31 normal controls with matching demographic features from the Shanghai community in China. Control participants were without cerebrovascular disease, as determined by magnetic resonance angiography. All patients received standard anti-platelets before being enrolled in the study. Participants were excluded if they exhibited significant neurological or psychiatric disorders, had severe systemic diseases, or presented with uncontrolled vascular risk factors that could affect cognition, such as hypertension, diabetes, dyslipidemia, drug abuse, or alcoholism. National Institutes of Health Stroke Scale (NIHSS) scores of all patients were assessed by two qualified neurosurgeons.

This study was approved by the Institutional Review Board in Huashan Hospital, China (approval No. 2014-278) (**Additional file 1**) and was conducted in accordance with the *Declaration of Helsinki*. All participants or their legal guardians provided informed consent. The trial was registered with Clinicaltrials.gov on December 2, 2014 (identifier NCT02304507) and the protocol version number is 1.0. A flowchart of the study is shown in **[Figure 1](#F1){ref-type="fig"}**. This study follows the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidance (**[Additional file 2](#T6){ref-type="table"}**).

![Flow chart for the study.\
MMD: Moyamoya disease; CAD: cerebrovascular atherosclerotic disease; SPECT: single-photo emission computed tomography.](NRR-14-858-g002){#F1}

Neuropsychological assessment {#sec2-2}
-----------------------------

An eligible neuropsychologist who was blinded to the patient diagnoses administered the neuropsychological tests. Global cognitive state was evaluated with the Mini-Mental State Examination (Chua et al., 2018). Additionally, long-term delayed recall results from long-term delayed recall of the Auditory Verbal Learning Test was used to assess episodic memory (Zhao et al., 2012b). The Trail Making Test Part B and the Symbol Digit Modalities Test were used to assess attention/executive function (Lu and Bigler, 2002; Wei et al., 2018). Specific cognitive assessment methods have been explained in detail in previous studies (Lei et al., 2014, 2016, 2017a, b).

Magnetic resonance imaging (MRI) {#sec2-3}
--------------------------------

An experienced technician, unaware of the study's purpose, performed the MRI scans. All MRI scans were performed on a 3.0 Tesla scanner (GE Healthcare, GE Asian Hub, Shanghai, China) using a 32-channel intraoperative head coil. The diffusion-weighted images were acquired using a single-shot spin-echo planar imaging sequence with the following parameters: 43 interleaved contiguous axial slices, slice thickness = 1.5 mm, repetition time = 8600 ms, flip angle = 90°, field of view = 270 × 270 mm^2^, matrix size = 128 × 128, number of excitations = 1, 30 diffusion-weighted volumes with non-collinear directions (b = 1000 s/mm^2^), and five non-diffusion-weighted volumes (b = 0 s/mm^2^). Total acquisition time was approximately 15 minutes.

Image preprocessing {#sec2-4}
-------------------

### Patterns of gray matter atrophy {#sec3-1}

To investigate differences in gray matter atrophy among the three groups, voxel-based morphometry (VBM) was carried out on all structural images using the VBM8 tool kit (<http://dbm.neuro.uni-jena.de>) for Statistical Parametric Mapping (SPM8, <http://www.fil.ion.ucl.ac.uk/spm/>) in the MATLAB environment (The MathWorks Inc., Natick, Massachusetts, United States). Preprocessing steps included: (1) normalizing the anatomical images using a high-dimensional nonlinear diffeomorphic registration algorithm by DARTEL to the Montreal Neurological Institute (MNI) template in 1.5 mm cubic resolution; (2) segmenting the spatially normalized images into gray matter, white matter, and cerebrospinal fluid; (3) smoothing the images with an 8-mm Gaussian kernel; (4) calculating the whole-brain gray matter volume for each group.

### Patterns of white matter deterioration {#sec3-2}

Diffusion-tensor imaging (DTI) data were examined for artifacts and signal dropout before pre-processing using the FMRIB Software Library view. High-quality DTI data were corrected according to the following criteria. FMRIB Software Library version 5.0 (<http://www.fmrib.ox.ac.uk/fsl>) was used for pre-processing. First, each participant's original data were corrected for eddy-current distortions and head motions using the eddy-correct command in FMRIB's Diffusion Toolbox. The correction was carried out by registering the individual volumes to the b0 images. Next, the skull was removed from the b0 image using the Brain Extraction Tool (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/BET>) (Smith, 2002) and the corresponding brain mask was applied to the eddy-corrected diffusion-weighted images. Fractional anisotropy (FA) and mean diffusivity (MD) of each voxel were calculated using the 'dtifit' command in FMRIB's Diffusion Toolbox.

Tract-based spatial statistics were applied to the FA and MD values using FMRIB's Diffusion Toolbox to investigate white matter integrity and diffusion characteristics. Individual FA images were registered non-linearly to the FMRIB58 template in MNI space and then averaged over all individuals to generate a mean FA image. Next, a study-specific FA skeleton was created from the generated mean FA map, which represented the core of the white matter tracts for all participants. The FA values were thresholded at 0.2 to avoid including any gray matter. Each subject's FA and MD images were projected onto this skeleton. The between-group difference was examined using FMRIB Software Library's permutation tool (1000 permutations) with the inclusion of gender and age as covariates, and a cluster significance level of *P* \< 0.05, corrected with threshold-free cluster enhancement.

Evaluation of hemodynamic status {#sec2-5}
--------------------------------

Single-photon emission-computed tomography/CT (Siemens, Symbia T16, Erlangen, Germany) was used to evaluate perfusion values in each brain region. Patients relaxed in the Oblique position, closing their eyes in a dark and quiet room for 30 minutes, and single-photon emission-computed tomography/CT scans were obtained after an intravenous injecting 1480 MBq of ^99m^Tc-ethyl cysteinate dimer (Neurolite, Bristol-Myers Squibb Pharma). Data were collected into a 128 × 128 matrix through a 360° rotation at steps of 2.8° for 80,000 counts per view. Filtered back-projection was employed using ordered subset-expectation materialization for reconstructing the images. Quantification of ach brain-perfusion single-photon emission-computed tomography/CT study was accomplished using the NeuroGam software package (Segami Corporation). This software applies AFNI anatomical coregistration through blocks of data defined in the Talairach space. The acquisition time for single-photon emission computed tomography/CT was 30 minutes.

Specific tracer-uptake ratios were bilaterally assessed for the region of interests in four consecutive transverse slices with highest radioactivity, and the arithmetic mean of these four slices was calculated. The cerebellums served as the reference regions and were drawn in the same way on two consecutive transverse slices. The specific tracer-uptake ratio was calculated as target divided by cerebellum, where the target represented bilateral frontal lobe, parietal lobe, occipital lobe, or thalamus.

Statistical analysis {#sec2-6}
--------------------

Statistical analysis and database management were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Differences among groups were tested *via* one-way analysis of variance, Fisher's exact test, and Kruskal-Wallis rank test, while *post hoc* tests with Bonferroni correction were used for further comparisons. Significance was set at *P* \< 0.05.

Voxel-wise comparison was carried out on gray matter volumes using SPM8. Results were assessed at *P* \< 0.05/3 (FDR corrected) for multiple comparisons. Skeletonized FA and MD maps were analyzed *via* group comparison. Voxel-wise statistics was performed across participants using Randomise, a FMRIB Software Library tool for nonparametric permutation. A null distribution was built for each contrast based on 5000 random permutations. Threshold-free cluster enhancement with corrected *P* \< 0.05/3 was used in the comparison (Hua et al., 2008). For visualization purposes, tracts were dilated using the "tbss-fill" command from the FMRIB Software Library. Regions in major white matter tracts that exhibited significant changes in FA and MD were later defined using the John Hopkins University white matter atlases in MNI space (Wakana et al., 2007; Avelar et al., 2015).

Results {#sec1-3}
=======

Demographic, neuropsychological, and hemodynamic features for patients with moyamoya disease or cerebrovascular atherosclerotic disease and for normal controls {#sec2-7}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Patient characteristics are summarized in **[Table 1](#T1){ref-type="table"}**. The three groups did not show significant differences in age, sex, education level, or controlled vascular risk factors, except for treated for hypercholesterolemia (*F* = 1.222; *P* \< 0.05). Further, National Institutes of Health Stroke Scale (NIHSS) scores did not differ between the two patient groups (moyamoya disease *vs*. cerebrovascular atherosclerotic disease: 1.5 ± 1.8 *vs*. 1.8 ± 1.7; z = 0.676, *P* = 0.499).

###### 

Demographic and neuropsychological features for patients and normal controls

  Index                          MMD (*n* = 34)   CAD (*n* = 27)   Normal controls (*n* = 31)   *F*/*χ*^2^ value (*P* value)
  ------------------------------ ---------------- ---------------- ---------------------------- ------------------------------
  Age (years)                    43.9±9.2         44.6±7.6         43.6±7.3                     0.528(0.768)
  Men                            20(58.8)         17(63.0)         18(58.1)                     0.165(0.921)
  Education (years)              8.7±5.1          9.7±3.9          9.4±4.0                      0.933(0.627)
  Treated hypertension           11(32.4)         12(44.4)         10(32.3)                     1.222(0.543)
  Treated hypercholesterolemia   10(29.4)         23(85.2)         7(22.6)                      (\< 0.001)^a^
  Treated diabetes               5(14.7)          7(25.9)          3(9.7)                       (0.257)^a^
  Smoking                        12(35.3)         11(40.7)         9(29.0)                      0.878(0.645)
  Cognitive status                                                                              
   MMSE                          25.3±3.8         26.4±2.1         28.2±1.7                     14.738(0.006)^b^
   AVLT-LR                       3.2±2.6          4.1±2.8          6.2±2.8                      9.96(\< 0.001)
   TMT-B (seconds)               178.2±58.3       161.6±60.0       119.0±37.3                   16.447(\< 0.001)^b^
   SDMT                          26.8±14.3        32.4±13.7        43.1±9.3                     24.138(\< 0.001)^b^

Data are expressed as the mean ± SD for age, education, and cognitive status assessment results, and number (percent) in other indices, ^a^Fisher's exact test. ^b^Kruskal-Wallis rank test. MMSE: Mini-Mental State Examination; AVLT-LR: long-term delayed recall of the Auditory Verbal Learning Test (a 20-minute delay time); TMT: Trail Making Test; TMT-B: time of TMT Part B; SDMT: Symbol Digit Modalities Test; MMD: moyamoya disease; CAD: cerebrovascular atherosclerotic disease.

Significant group differences were found for Mini-Mental State Examination (*F* = 14.738; *P* = 0.006), long-term delayed recall of Auditory Verbal Learning Test (*F* = 9.96; *P* \< 0.001), Symbol Digit Modalities Test (*F* = 16.447; *P* \< 0.001), and The Trail Making Test Part B scores (*F* = 24.138; *P* \< 0.001). Further analysis indicated that patients with moyamoya disease performed significantly worse than normal controls on the Mini-Mental State Examination (*z* = 3.375, *P* \< 0.001), long-term delayed recall of Auditory Verbal Learning Test (*P* \< 0.001), Symbol Digit Modalities Test (*z* = 4.555, *P* \< 0.001), and The Trail Making Test Part B (*z* = 3.953, *P* \< 0.001). Similarly, patients with cerebrovascular atherosclerotic disease performed significantly worse than normal controls on the Mini-Mental State Examination (*z* = 3.307, *P* \< 0.001), long-term delayed recall of Auditory Verbal Learning Test (*P* = 0.015), Symbol Digit Modalities Test (*z* = 3.613, *P* \< 0.001), and The Trail Making Test Part B (*z* = 2.801, *P* = 0.005). However, no significant differences were found between the two patient groups on any of these neuropsychological tests.

Both moyamoya disease and cerebrovascular atherosclerotic disease group demonstrated lower perfusion in supratentorial regions compared with the control group. Post hoc analysis showed lower perfusion in the thalamus of the cerebrovascular atherosclerotic disease group than in the control group, but the difference was not significant. The hemodynamic features among the three groups showed a moyamoya disease \< cerebrovascular atherosclerotic disease \< controls pattern for all brain regions except the left occipital lobe (**[Table 2](#T2){ref-type="table"}**).

###### 

Hemodynamic differences among patients and normal controls

                           MMD         CAD         Normal controls   *P* value   Adjusted *P* value           
  ------------------------ ----------- ----------- ----------------- ----------- -------------------- ------- ---------
  Left frontal cortex      0.82±0.03   0.86±009    0.98±0.06         0.003       0.001                0.009   0.335
  Right frontal cortex     0.84±0.13   0.87±0.11   0.98±0.09         0.001       \< 0.001             0.004   0.09
  Left parietal cortex     0.91±0.13   0.92±0.10   1.05±0.08         0.001       0.001                0.001   0.941
  Right parietal cortex    0.87±0.13   0.93±0.11   1.05±0.11         0.001       \< 0.001             0.012   0.136
  Left temporal cortex     0.83±0.11   0.84±0.09   0.93±0.06         0.006       0.002                0.008   0.597
  Right temporal cortex    0.83±0.11   0.87±0.10   0.96±0.08         0.007       0.002                0.029   0.232
  Left occipital cortex    1.07±0.15   1.07±0.10   1.13±0.09         0.262       0.11                 0.187   0.765
  Right occipital cortex   0.84±0.13   0.87±0.11   0.98±0.09         0.02        0.15                 0.247   0.063
  Left thalamus            0.80±0.15   0.87±0.10   0.96±0.08         0.03        0.03                 0.683   0.028
  Right thalamus           0.79±0.14   0.91±0.06   0.93±0.11         \< 0.001    \< 0.001             0.644   \<0.001

Data are expressed as the tracer uptake radio (mean ± SD; one-way analysis of variance followed by Bonferroni *post hoc* test). MMD: Moyamoya disease; CAD: cerebrovascular atherosclerotic disease.

Gray matter atrophy patterns among moyamoya disease patients, cerebrovascular atherosclerotic disease patients, and normal controls {#sec2-8}
-----------------------------------------------------------------------------------------------------------------------------------

Differences in gray matter volume among the three groups are highlighted in **[Figure 2](#F2){ref-type="fig"}** (corrected *P* \< 0.05/3). Compared with controls, the moyamoya disease group exhibited widespread loss of gray matter volume, particularly in the frontal cortex (bilateral middle frontal gyrus, middle cingulate cortex, left superior frontal gyrus, and left orbitofrontal gyrus). Compared with controls, the cerebrovascular atherosclerotic disease group exhibited significantly lower gray matter volume in the frontal cortex (particularly in left medial superior frontal gyrus and bilateral middle cingulate cortex) and the parietal cortex (left superior parietal gyrus). Interestingly, the cerebrovascular atherosclerotic disease group presented a pattern of gray matter atrophy in the medial part of the brain.

![Comparison of gray matter volume (MRI T1) among patients and normal controls.\
(A) Gray matter volume (GMV) reduction in MMD compared with controls; (B) GMV reduction in CAD compared with NC; (C) GMV reduction in MMD compared with CAD; (D) GMV reduction in CAD compared with MMD. Significance threshold set at FDR-corrected *P* \< 0.05/3. Colored bars represent Z values. GMV: Gray matter volume; MMD: moyamoya disease; CAD: cerebrovascular atherosclerotic disease; NC: normal controls; MFG: middle frontal gyrus; MOG: middle occipital gyrus; SFG: superior frontal gyrus; OFG: orbitofrontal gyrus; mSFG: medial superior frontal gyrus; SPG: superior parietal gyrus; MCC: middle cingulate cortex; PCu: precuneus; IG: insular gyrus.](NRR-14-858-g003){#F2}

Gray matter volume was significantly less in the moyamoya disease group than in the cerebrovascular atherosclerotic disease group for the left superior frontal gyrus, left middle frontal gyrus, and left precuneus. In contrast, gray matter volume was significantly less in the cerebrovascular atherosclerotic disease group than in the moyamoya disease group for the left medial superior frontal gyrus and bilateral insular gyrus (**[Table 3](#T3){ref-type="table"}**).

###### 

Z-statistical maps of gray matter volume differences among patients and normal controls

                  Brain regions                        Volume (mm^3^)   MNI coordinates (mm)   Maximum *Z*          
  --------------- ------------------------------------ ---------------- ---------------------- ------------- ------ -------
  NC *vs*. MMD    Right middle frontal gyrus           3834             30                     51            33     5.937
                  Left middle frontal gyrus            7614             --30                   45            27     5.767
                  Left middle cingulate cortex         1728             --9                    --3           39     5.204
                  Right middle cingulate cortex        1476             9                      0             36     5.126
                  Left superior frontal gyrus          4482             --21                   --6           60     4.854
                  Left orbitofrontal gyrus             1746             --18                   60            --12   4.478
                  Left middle occipital gyrus          1332             --24                   --72          30     4.465
                  Right middle occipital gyrus         2205             36                     --78          27     4.140
                  Right middle temporal gyrus          1935             48                     --27          --6    4.074
  NC *vs*. CAD    Left medial superior frontal gyrus   7911             --9                    60            12     5.333
                  Left superior parietal gyrus         1539             --18                   --69          45     5.074
                  Right middle cingulate cortex        2592             12                     6             42     4.885
                  Left middle cingulate cortex         2061             --3                    --42          54     3.801
  CAD *vs*. MMD   Left superior frontal gyrus          1512             --18                   9             60     4.451
                  Left middle frontal gyrus            1323             --33                   39            21     4.340
                  Left precuneus                       792              --9                    --66          57     3.606
  MMD *vs*. CAD   Left medial superior frontal gyrus   2025             --3                    60            9      3.937
                  Right insular gyrus                  1242             45                     0             --6    3.598
                  Left insular gyrus                   729              --42                   --6           --3    3.525

*x*, *y*, *z*: Peak MNI coordinates; *Z*: statistical value for the voxel showing peak gray matter volume differences among groups (adjusted for age and sex, corrected *P* \< 0.05/3). MNI: Montreal Neurological Institute; NC: normal control; MMD: moyamoya disease; CAD: cerebrovascular atherosclerotic disease.

White matter deterioration patterns among moyamoya disease patients, cerebrovascular atherosclerotic disease patients, and normal controls {#sec2-9}
------------------------------------------------------------------------------------------------------------------------------------------

We further looked for white matter deterioration patterns in the two patient groups (**[Figure 3](#F3){ref-type="fig"}**; corrected *P* \< 0.05/3; threshold-free cluster enhancement). Compared with controls, FA was significantly lower and MD was significantly higher throughout widespread white matter tracts in the moyamoya disease group. Lower FA was observed in the genu, body, and splenium of the corpus callosum, the internal and external capsule, anterior and superior corona radiation, cingulum, superior longitudinal fasciculus, and a portion of the posterior thalamic radiation. Higher MD was more extensive in the same white matter tracts. No regions of significantly higher FA or significantly lower MD were found in the moyamoya disease group.

![Tract-based spatial statistical analysis (Montreal Neurological Institute diffusion-tensor imaging) of FA decrease and MD increase among patients and normal controls.\
(A) FA decrease (red); (B) MD increase (purple). Demographic variables were controlled for and results are overlaid on the MNI152 template and the mean diffusion tensor imaging metrics skeleton (green). Significance: corrected *P* \< 0.05/3; threshold-free cluster enhancement. ACR: Anterior corona radiate; BCC: body of corpus callosum; SCC: splenium of the corpus callosum; PTR: posterior thalamic radiation; CGC: cingulum; EC: external capsule; GCC: genu of corpus callosum; IC: internal capsule; SLF: superior longitudinal fasciculus; SCR: superior corona radiate; NC: normal controls; FA: Fractional anisotropy; MD: mean diffusivity; MMD: moyamoya disease; CAD: cerebrovascular atherosclerotic disease.](NRR-14-858-g004){#F3}

Similarly, we found that FA was significantly lower and MD was significantly higher in the central part of the white matter tracts in the cerebrovascular atherosclerotic disease group compared with controls, including a portion of the genu and body of corpus callosum, cingulum, posterior thalamic radiation, anterior corona radiata, and part of superior corona radiata. Higher MD was more extensive in these same white matter tracts. In addition, higher MD was also found in the bilateral internal and external capsule of the cerebrovascular atherosclerotic disease group. FA was not higher in the cerebrovascular atherosclerotic disease group than in controls, nor was MD lower (**Tables [4](#T4){ref-type="table"}** and **[5](#T5){ref-type="table"}**).

###### 

Permutation test for differences in fractional anisotropy among patients and normal controls

                  Cluster   Volume (mm^3^)   MNI coordinates (mm)   *P*    Anatomical region               
  --------------- --------- ---------------- ---------------------- ------ ------------------- ----------- ---------------------------------------
  NC *vs*. MMD    1         7529             42                     --6    --16                \< 0.05/3   Genu of corpus callosum
                                                                                                           Internal capsule
                                                                                                           External capsule
                                                                                                           Splenium of the corpus callosum
                                                                                                           Posterior thalamic radiation
                  2         786              --30                   --60   --4                 \< 0.05/3   Anterior corona radiate
                                                                                                           Cingulum
                                                                                                           Body of corpus callosum
                                                                                                           Superior longitudinal fasciculus
                  3         279              26                     --58   38                  \< 0.05/3   Left superior corona radiate
  NC *vs*. CAD    1         3041             8                      --26   4                   \< 0.05/3   Genu of corpus callosum
                                                                                                           Left anterior corona radiate
                                                                                                           Right posterior thalamic radiation
                  2         789              14                     48     26                  \< 0.05/3   Body of corpus callosum
                                                                                                           Cingulum
                  3         247              --24                   --44   46                  \< 0.05/3   Left superior corona radiate
  CAD *vs*. MMD   1         237              --32                   --20   54                  \< 0.05/3   Left superior corona radiate
                                                                                                           Left superior longitudinal fasciculus

Results are bilateral unless a hemisphere is specified. x, y, z: Peak coordinates in MNI space. MNI: Montreal Neurological Institute; MMD: moyamoya disease; CAD: cerebrovascular atherosclerotic disease; NC: normal control.

###### 

Permutation test for differences in mean diffusivity among patients and normal controls

                  Cluster   Volume (mm^3^)   MNI coordinates (mm)   *P*    Anatomical region               
  --------------- --------- ---------------- ---------------------- ------ ------------------- ----------- ----------------------------------
  NC *vs*. MMD    1         6431             43                     --10   --15                \< 0.05/3   Genu of corpus callosum
                                                                                                           Internal capsule
                                                                                                           External capsule
                                                                                                           Splenium of the corpus callosum
                                                                                                           Anterior corona radiate
                                                                                                           Posterior thalamic radiation
                  2         783              --29                   --63   --5                 \< 0.05/3   Superior corona radiate
                                                                                                           Cingulum
                                                                                                           Body of corpus callosum
                                                                                                           Superior longitudinal fasciculus
                  3         280              27                     --60   42                  \< 0.05/3   Superior corona radiate
  NC *vs*. CAD    1         3022             9                      --39   5                   \< 0.05/3   Genu of corpus callosum
                                                                                                           Anterior corona radiate
                                                                                                           External capsule
                                                                                                           Internal capsule
                  2         801              16                     50     29                  \< 0.05/3   Body of corpus callosum
                                                                                                           Anterior corona radiate
                  3                                                                                        Left superior corona radiate
  CAD *vs*. MMD   1         312              --26                   --26   67                  \< 0.05/3   Anterior corona radiate
                                                                                                           Posterior thalamic radiation
                  2         214              24                     16     48                  \< 0.05/3   Superior longitudinal fasciculus

Results are bilateral unless a hemisphere is specified. x, y, z: Peak coordinates in MNI space. MNI: Montreal Neurological Institute; MMD: moyamoya disease; CAD: cerebrovascular atherosclerotic disease; NC: normal control.

The white matter damage was more diffuse and severe in the moyamoya disease group than in the cerebrovascular atherosclerotic disease group. In particular, FA was significantly lower in the moyamoya disease group in parts of the anterior and superior corona radiata and in the superior longitudinal fasciculus. Moreover, higher MD was primarily found in part of the anterior corona radiata, posterior thalamic radiation, and superior longitudinal fasciculus. In contrast, the cerebrovascular atherosclerotic disease group did not exhibit any significantly lower FA or any significantly higher MD than the moyamoya disease group (**Tables [4](#T4){ref-type="table"}** and **[5](#T5){ref-type="table"}**).

Discussion {#sec1-4}
==========

To date, with increasing reports of cognitive impairment in patients with chronic cerebrovascular diseases, the diagnoses and treatments of vascular cognitive impairment are becoming more of a concern (Gorelick et al., 2011; Kazumata et al., 2015; Meng et al., 2017; He et al., 2018; Weinstein, 2018). However, most published studies of vascular cognitive impairment are based on only a single disease, making it difficult to discern common vascular cognitive impairment features from individual disease pathophysiology. In the present study, we conducted a cross-sectional neuroimaging analysis of two chronic cerebrovascular diseases commonly reported in the field of vascular cognitive impairment. Results indicated that (1) moyamoya disease and cerebrovascular atherosclerotic disease exhibited supratentorial impaired cerebral perfusion, with greater hypoperfusion in the moyamoya disease group; (2) moyamoya disease and cerebrovascular atherosclerotic disease groups exhibited significant gray matter atrophy in the bilateral middle cingulate cortex and parts of the frontal gyrus, with but the atrophy in the moyamoya disease group being more diffuse and severe; (3) moyamoya disease and cerebrovascular atherosclerotic disease groups showed significant white matter deterioration in the genu and body of corpus callosum, anterior and superior corona radiations, cingulum, and posterior thalamic radiation. White matter deterioration in the moyamoya disease group was more diffuse and severe than that in the cerebrovascular atherosclerotic disease group.

Previous studies have reported structural and functional damage to the frontal cortex caused by hemodynamic disturbances is a major cause of vascular cognitive impairment (Calviere et al., 2012; Lei et al., 2014; Chen et al., 2016; Fang et al., 2016). Additionally, the middle cingulate cortex is reported to be the main hub for the impulse control network. It connects to the frontal regions related to decision making and affects vascular cognitive impairment (Shackman et al., 2011). In the present study, gray matter atrophy was significant in the bilateral middle cingulate cortex and parts of the frontal gyrus in both moyamoya disease and cerebrovascular atherosclerotic disease groups, implying that vascular cognitive impairment might result from regional gray matter atrophy.

While gray matter comprises neuronal cell bodies, white matter is made from the myelinated axons that connect neurons to each other. In this study, white matter tract abnormalities were identified in the genu and body of corpus callosum, the anterior and superior corona radiations, and the posterior thalamic radiation in both moyamoya disease and cerebrovascular atherosclerotic disease, indicating that this pattern of damage to white matter tracts might be characteritic of vascular cognitive impairment. The corpus callosum is the largest white matter tract in the brain and plays a vital role in executive function, such as processing speed and problem solving abilities (van Eimeren et al., 2008; Penke et al., 2010). In addition, both the corona radiation and posterior thalamic radiation contain fibers that transfer information between the thalamus and the cerebral cortex. Their common pattern of white matter tract damage may be due to a common hemodynamic disturbance (Schubert et al., 2014).

In the present study, the moyamoya disease group presented a widespread pattern of damage to gray and white matter, while the cerebrovascular atherosclerotic disease group presented a more central and medial pattern of damage. This implies a potential link between gray matter and white matter damage. There are two possible explanations. First, neuronal cell bodies and axons are parts of the same cell, and physiological and anatomical studies show that they often are impaired together under pathological conditions. For example, when white matter tracts deteriorate after demyelination, the signal conduction along the nerve is impaired, which leads to withering of the nerve and somatic atrophy. Kazumata et al. (2015) also noted a positive link between focally damaged gray and white matter in another MDD study. Subsequently, chronic hemodynamic deficiencies, inflammation, and other factors lead to unique collateral and microstructural damage in MDD and cerebrovascular atherosclerotic disease (Masuda et al., 1993; Vermeer et al., 2003; Bos et al., 2012; Blecharz et al., 2017). Furthermore, Schubert et al. (2014) also noticed territory-specific patterns of cerebral blood flow in a previous study comparing the two diseases. Thus, we speculated that vascular cognitive impairment is a heterogeneous complication and a consequence of both hemodynamic compromise and other coexisting disruptive factors.

In addition to describing the cognitive impairment of moyamoya disease and cerebrovascular atherosclerotic disease, this study is particularly interested in establishing a methodology for detecting and monitoring disease progression in future studies of this particular patient population. Moreover, the data presented in this study can be used as a good cornerstone for monitoring the efficacy of surgical revascularization (Amin-Hanjani and Charbel, 2006).

Some limitations of this study should be considered. Primarily, the present study excluded patients with obvious structural abnormalities or early stage vascular cognitive impairment (Reis et al., 2013; Kazumata et al., 2015). Moreover, the small sample size limits the statistical power. Finally, tract-based spatial statistics and VBM analysis can only do group comparisons, but cannot do individual analysis. Additionally, it is technically difficult to balance type-I and type-II errors in terms of what corrective methods are used in the VBM analysis.

Taken together, the present study provides valuable information about the spatial patterns of microstructural damage in vascular cognitive impairment by comparing two chronic cerebrovascular diseases. Future studies are needed to explore the relationship between microstructural damage and cognitive performance in vascular cognitive impairment patients.
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  Interpretation                                                                                                          20        Give a cautious overall interpretation of results considering objectives, limitations,multiplicity of analyses, results from similar studies, and other relevant evidence √
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  Funding                                                                                                                 22        Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based √
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